Comparing Low and Standard Energy Laser Treatment for Glaucoma
Tests low-energy laser treatment for glaucoma and eye pressure in adults.
Plain-language title generated from the registry record
Registry title: Clarifying the Optimal Application of SLT Therapy Trial
Key facts
- Where
- Ann Arbor, Baltimore, Boston, Chicago, Cleveland, Detroit, Fort Worth, Kingston, Laguna Hills, Lakeworth, Madison, Morgantown, Nashville, Orland Park, Pasadena, Peoria, Philadelphia, Pittsburgh, Portland, Reading, Sacramento, San Francisco, Sheridan, Spokane, and The Bronx, United StatesSee the 28 sites
- Phase
- Phase 3
Where in United States
- University of Michigan Kellogg Eye CenterAnn Arbor, United StatesTaking people
- Wilmer Eye Institute Johns HopkinsBaltimore, United StatesTaking people
- Massachusetts Eye and EarBoston, United StatesTaking people
- Ophthalmic Consultants of BostonBoston, United StatesTaking people
- Northwestern Medical GroupChicago, United StatesTaking people
- Cleveland Clinic Cole Eye InstituteCleveland, United StatesTaking people
- University Hospitals Eye InstituteCleveland, United StatesTaking people
- Kresge Eye Institute Wayne State UniversityDetroit, United StatesTaking people
- Ophthalmology AssociatesFort Worth, United StatesTaking people
- Eye Care SpecialistsKingston, United StatesTaking people
- Harvard Eye AssociatesLaguna Hills, United StatesTaking people
- Clear Vue Laser Eye CenterLakeworth, United StatesTaking people
- University of Wisconsin - MadisonMadison, United StatesTaking people
- West Virginia UniversityMorgantown, United StatesTaking people
- Vanderbilt Eye InstituteNashville, United StatesTaking people
- Chicago Arbor Eye InstituteOrland Park, United StatesTaking people
- Doheny Eye Center UCLAPasadena, United StatesTaking people
- Illinois Eye CenterPeoria, United StatesTaking people
- Scheie Eye InstitutePhiladelphia, United StatesTaking people
- Wills Eye HospitalPhiladelphia, United StatesTaking people
- UPMC Eye CenterPittsburgh, United StatesNo longer taking part
- Devers Eye InstitutePortland, United StatesTaking people
- Mark Latina, LLCReading, United StatesTaking people
- University of California - DavisSacramento, United StatesTaking people
- University of California San FranciscoSan Francisco, United StatesTaking people
- Mile High Eye InstituteSheridan, United StatesTaking people
- Spokane Eye Clinical ResearchSpokane, United StatesTaking people
- New York Eye Surgery AssociatesThe Bronx, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Pittsburgh
- Trial code
- NCT04967989
- Record updated
- 14 August 2026
- Original description
The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.Read full original descriptionShow less
Clarifying the Optimal Application of SLT Therapy Trial
The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.
Inclusion: Age 18 or older and in good health; Each eye with one of the following qualifying diagnoses (diagnoses may differ between eyes):; High-risk ocular hypertension (OHT): IOP > 21 mmHg without glaucomatous optic neuropathy (excavation, diffuse or focal thinning or notching of the neuroretinal rim, visible nerve fiber layer defects, or asymmetry of the vertical cup-to-disc ratio of >0.2 between eyes); Mild primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation better than -6.0 dB with no points in the central 5° <15 dB (see figure on next page); Moderate primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation equal to or worse than -6.0 dB but no worse than -12.0 dB and no central 5° points <15 dB or mean deviation -12.0 dB or better with 1 central 5° points <15 dB (see figure on next page); Each eye with BCVA 20/200 (UK 6/60) or better.
Exclusion: Use of topical IOP-lowering medications for more than 6 cumulative months at any time in the past 5 years (this is a modification implemented during active enrollment); Any intraocular surgical procedure within the past 6 months in either eye; Any history of IOP-lowering laser (prophylactic iridotomy not included) or surgical procedure; Advanced POAG in either eye (worse than moderate POAG as defined above); Glaucoma other than POAG (including pigmentary and pseudoexfoliation glaucoma) in either eye; Mean IOP > 35 mmHg at either the screening or baseline visit in either eye; Narrow or closed angle (Shaffer Grade 0, 1, or 2) in either eye; Contraindications to SLT or any other study intervention; Any corneal pathology that would preclude accurate assessment of IOP by Goldmann tonometry in either eye; Inability to attend all scheduled study visits; Pregnant or planning to become pregnant in the next 4 years.